In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2 ...

AbbVie’s treatment, emraclidine, which it got the drug through its $9 billion acquisition of Cerevel Therapeutics, failed to significantly help patients.

AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie ...

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of ...

(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the emraclidine intangible asset acquired as part of the ...

AbbVie saw a 10% drop after its drug emraclidine failed in trials. Find out why ABBV stock is struggling and how this affects its long-term prospects.

Emraclidine is also being developed for Alzheimer's Disease Psychosis, with a phase 1 study already initiated. The company has a well-capitalized financial position and multiple upcoming data ...

The company isn't ready to give up on emraclidine yet — and it has other neuroscience drugs in its pipeline that could show potential soon.

Cerevel’s phase 2 program for emraclidine continues, with a readout focused on efficacy expected in the first half of 2024. The biotech is hoping to position the therapy as a new standard of ...

Emraclidine had been seen as a way to keep pace in the space. When AbbVie purchased Cerevel, it said the biotech “positions us to deliver sustainable long-term performance into the next decade ...

The EMPOWER clinical development program evaluated emraclidine in patients with schizophrenia who are experiencing an acute exacerbation in two adequately-powered, placebo-controlled Phase 2 ...